[{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131 Group","sponsor":"CURIUM US LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Radiolabelled Compounds","year":"2025","type":"Acquisition","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Eczac\u0131ba\u015f\u0131 Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eczac\u0131ba\u015f\u0131 Group \/ CURIUM US LLC","highestDevelopmentStatusID":"10","companyTruncated":"Eczac\u0131ba\u015f\u0131 Group \/ CURIUM US LLC"},{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","sponsor":"FutureChem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"177-Ludotadipep","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem","highestDevelopmentStatusID":"6","companyTruncated":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem"}]

Find Clinical Drug Pipeline Developments & Deals by Eczacıbaşı Group

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : The acquisition enhances Curium’s manufacturing of Lutetium-177 to meet the growing demand for isotope around the world. Curium’s Lu-177 (Lutetium-177 PSMA-I&T) is being evaluated for Prostate Cancer.

                          Product Name : Curium Lu-177

                          Product Type : Radiolabelled Compounds

                          Upfront Cash : Undisclosed

                          March 28, 2025

                          Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : CURIUM US LLC

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : 177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding.

                          Product Name : 177-Lu FC705

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 18, 2022

                          Lead Product(s) : 177-Ludotadipep

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : FutureChem

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank